Literature DB >> 3444388

Alkyl phosphocholines: toxicity and anticancer properties.

C Muschiol1, M R Berger, B Schuler, H R Scherf, F T Garzon, W J Zeller, C Unger, H J Eibl, D Schmähl.   

Abstract

The study reports on the investigation of acute and subacute toxicity and on antineoplastic activity of hexadecylphosphocholine (HPC), the first compound of a new class of antineoplastic chemotherapeutics. In rats, the LD50 of HPC was 606 mumol/kg; the maximum tolerable dose over four weeks was 39 mumol/kg. Symptoms of toxicity were enteritis, spider cell activation in the liver, hemosiderosis in the spleen and reversible transaminase increase. The best therapeutic effect was observed on methylnitrosourea (MNU)-induced mammary carcinoma in the rat. Two transplantable mammary carcinomas in the rat and autochthonous benzo(a)pyrene-induced sarcomas exhibited low-grade sensitivity to HPC. The MXT mammary carcinoma of the mouse, the Walker 256 carcinosarcoma of the rat, and autochthonous acetoxymethylmethylnitrosamine-induced colonic tumors of the rat were not chemosensitive to HPC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3444388     DOI: 10.1007/BF02535558

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  7 in total

1.  [Effect of dose and tumor size on the response of autochtonous benzopyrene sarcomas in rats and mice to chemotherapeutic treatment with Endoxan].

Authors:  D Schmähl; H Osswald; H Brune
Journal:  Z Krebsforsch       Date:  1968

2.  Noncarcinogenic chemotherapy with a combination of vincristine, methotrexate and 5-fluorouracil (VMF) in rats.

Authors:  M Berger; M Habs; D Schmähl
Journal:  Int J Cancer       Date:  1983-08-15       Impact factor: 7.396

3.  Preclinical drug development: rationale and methods.

Authors:  J M Venditti
Journal:  Semin Oncol       Date:  1981-12       Impact factor: 4.929

4.  A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment.

Authors:  J A Koziol; D A Maxwell; M Fukushima; M E Colmerauer; Y H Pilch
Journal:  Biometrics       Date:  1981-06       Impact factor: 2.571

5.  Chemotherapy studies in autochthonous rat tumors intestinal cancer.

Authors:  F Sych; M Habs; D Schmähl
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-08-24

6.  Chemotherapeutic studies on N-nitrosoacetoxymethyl-methylamine-and 1,2-dimethylhydrazine-induced colonic tumors in rats: monotherapy with 5-fluorouracil, ftorafur, CGP 6809, and CGP 15'720A.

Authors:  I Wagner; M Habs; D Schmähl; H Amberger; U Bachmann
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

7.  Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.

Authors:  H R Scherf; B Schuler; M R Berger; D Schmähl
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

  7 in total
  19 in total

1.  [Spectrographic studies on the radioresistance of Miltex and miltefosine].

Authors:  G Bollmann; H Paukisch; E Bothe; W Strate; G Gademann
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

Review 2.  Alkylphosphocholines: a new class of membrane-active anticancer agents.

Authors:  P Hilgard; T Klenner; J Stekar; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy.

Authors:  E Petru; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  Effects of antineoplastic phospholipids on parameters of cell differentiation in U937 cells.

Authors:  C Hochhuth; D Berkovic; H Eibl; C Unger; D Doenecke
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

5.  Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in Mouse Brain.

Authors:  Mehran Nikan; Maire F Osborn; Andrew H Coles; Annabelle Biscans; Bruno M D C Godinho; Reka A Haraszti; Ellen Sapp; Dimas Echeverria; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Bioconjug Chem       Date:  2017-05-10       Impact factor: 4.774

6.  Hexadecylphosphocholine differs from conventional cytostatic agents.

Authors:  M R Berger; B Betsch; M Gebelein; E Amtmann; P Heyl; H R Scherf
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Effect of ether lipids on mouse granulocyte-macrophage progenitor cells.

Authors:  K Vehmeyer; D J Kim; G A Nagel; H Eibl; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.

Authors:  J Stekar; P Hilgard; R Voegeli; H R Maurer; J Engel; B Kutscher; G Nössner; W Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment.

Authors:  N Marschner; J Kötting; H Eibl; C Unger
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.

Authors:  H R Scherf; B Schuler; M R Berger; D Schmähl
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.